Paradigm Capital Management Inc. NY Takes $61.77 Million Position in Integra LifeSciences Holdings Corporation $IART

Paradigm Capital Management Inc. NY bought a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 3,439,098 shares of the life sciences company’s stock, valued at approximately $61,766,000. Integra LifeSciences comprises approximately 1.7% of Paradigm Capital Management Inc. NY’s portfolio, making the stock its 14th biggest position. Paradigm Capital Management Inc. NY owned approximately 4.42% of Integra LifeSciences at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in IART. Rubric Capital Management LP increased its position in Integra LifeSciences by 1.3% in the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after purchasing an additional 100,000 shares during the period. Invesco Ltd. lifted its position in Integra LifeSciences by 0.9% during the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after purchasing an additional 31,931 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Integra LifeSciences by 9.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after purchasing an additional 267,134 shares during the last quarter. State Street Corp boosted its stake in shares of Integra LifeSciences by 0.8% in the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock valued at $34,933,000 after purchasing an additional 21,717 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Integra LifeSciences by 8.8% during the 4th quarter. Geode Capital Management LLC now owns 1,683,964 shares of the life sciences company’s stock worth $20,918,000 after buying an additional 135,743 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART opened at $16.69 on Tuesday. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -185.42, a P/E/G ratio of 1.41 and a beta of 1.21. The firm’s 50 day simple moving average is $17.98 and its 200 day simple moving average is $14.11. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. Integra LifeSciences Holdings Corporation has a fifty-two week low of $8.70 and a fifty-two week high of $20.49.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The business had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, sell-side analysts forecast that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IART has been the topic of several analyst reports. BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price objective on the stock. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a report on Thursday, June 18th. UBS Group began coverage on shares of Integra LifeSciences in a research report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price for the company. Truist Financial increased their price target on Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research note on Thursday, July 16th. Finally, Citigroup restated a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Integra LifeSciences has a consensus rating of “Reduce” and an average price target of $18.86.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.